NewKerala.com

Budget 2026: Sitharaman Launches Rs 10,000 Crore Bio Pharma Shakti Plan

Finance Minister Nirmala Sitharaman has proposed a Rs 10,000 crore allocation over five years for the Bio Pharma Shakti programme to establish India as a biopharma hub. The budget also emphasizes scaling up manufacturing in strategic sectors and developing city economic regions. Sitharaman highlighted the government's focus on fiscal discipline and sustained growth since taking office. The Economic Survey projects India's real GDP growth for 2026-27 in the range of 6.8-7.2%, with inflation at a record low.

Key Points: Budget 2026: Rs 10,000 Cr for Biopharma Hub | Bio Pharma Shakti

  • Rs 10,000 crore Bio Pharma Shakti programme
  • Focus on biopharma & biosimilars ecosystem
  • GDP growth projected at 6.8-7.2%
  • Record low inflation of 1.7%
  • Scaling up strategic manufacturing
2 min read

Budget 2026: Sitharaman allocates Rs 10000 crore to make India biopharma hub

FM Nirmala Sitharaman allocates Rs 10,000 crore to make India a biopharma hub via Bio Pharma Shakti. GDP growth projected at 6.8-7.2%.

"Since we assumed office 12 years ago, India's economic trajectory has been marked by stability, fiscal discipline, sustained growth and moderate inflation. - Nirmala Sitharaman"

New Delhi, February 1

Finance Minister Nirmala Sitharaman has proposed to push India's biopharma sector under a Bio Pharma Shakti programme with an allocation of Rs 10000 crore for the next 5 years.

Bio Pharma Shakti is aimed at building at making ecosystem for biopharma and biosimilars, she said, presenting the Budget in the Parliament on Sunday.

Among other announcments, she proposed scaling up manufacturing in strategic and frontier sectors and developing city economic regions.

In her initial remarks, Finance Minister Nirmala Sitharaman said since her government assumed office, Indian economic trajectory is marked by fiscal discipline and sustained growth.

She stressed that the government led by Prime Minister Narendra Modi has chosen action over ambivalance, and reform over rhetoric, keeping Atmanirbharta or self-reliance as lodestar.

"Since we assumed office 12 years ago, India's economic trajectory has been marked by stability, fiscal discipline, sustained growth and moderate inflation," she said. She continued that India will balance ambition with inclusion going ahead.

Finance Minister Sitharaman presented her record ninth consecutive Union budget today in the Parliament.

On Thursday, Union Finance Minister Nirmala Sitharaman tabled the Economic Survey of India in Parliament for the financial year 2025-26.

The tabling of the Economic Survey ahead of the Budget follows the long-standing tradition of outlining the state of the economy before detailing future fiscal plans. The document provided a comprehensive, data-backed review of the economy's performance over the previous year and offers a broad roadmap for future policy direction. As the government's flagship annual report, it reviews key economic developments over the past 12 months.

India's real GDP growth for 2026-27 is projected in the range of 6.8-7.2 per cent, reflecting sustained medium-term growth capacity amid a challenging global environment.

India recorded the lowest inflation rate since the beginning of the CPI series, with April-December 2025 average headline inflation coming in at 1.7 per cent, attributing to general disinflationary trend in food and fuel prices. Looking ahead, the inflation outlook remains benign, supported by favourable supply side conditions and the gradual pass-through of GST rate rationalisation.

- ANI

Share this article:

Reader Comments

P
Priya S
Bio Pharma Shakti sounds promising. As someone working in healthcare, I've seen our dependence on imported biosimilars. If this programme can build a robust ecosystem, it will bring down medicine costs for critical diseases. Fingers crossed! 🤞
R
Rohit P
Good move, but Rs 10,000 crore seems modest for a 5-year national mission in such a capital-intensive sector. Hope it's seed funding to attract private investment. The real test will be in creating world-class research facilities, not just manufacturing units.
S
Sarah B
The focus on strategic sectors is crucial. The low inflation numbers are impressive, providing a stable base for such long-term investments. Hope this creates high-skilled jobs for our science graduates.
V
Vikram M
Finally! We missed the bus on semiconductors to some extent, but biopharma is where we can truly lead. Our generic pharma strength gives us a head start. Let's ensure the funds reach the innovators and startups, not just the big corporates.
N
Nisha Z
The budget speech had good points on fiscal discipline. But as a common citizen, I hope this 'Bio Pharma Shakti' translates to affordable insulin and cancer drugs for my family. That's the real measure of success. Jai Hind.

We welcome thoughtful discussions from our readers. Please keep comments respectful and on-topic.

Leave a Comment

Minimum 50 characters 0/50